Probiotics in the management of ulcerative colitis

Gastroenterology and Hepatology

Volumn 6, Issue 11, 2010, Pages 688-690

  Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLORASTOR; MESALAZINE; MUTAFLOR; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL3;

BACTERIAL VIABILITY; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM INFANTIS; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; NONHUMAN; NOTE; PATHOPHYSIOLOGY; REMISSION; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 78650456112     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005; 100:1539-1546.
2. Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol. 2008;42:S111-S115.
3. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 2010;10:13.
4. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639.
5. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202-1209.